Searched for
WCK 5222
Wockhardt Q2 Results: Net loss narrows to Rs 16 crore, revenue rises 7%Drugmaker Wockhardt on Wednesday reported a net loss of Rs 16 crore in Q2FY25 led by improved performance across UK, India and emerging mar...- IT now a tactical buy, not a portfolio bet; 4 other stocks to invest in: Vinit BolinjkarIT stocks can be considered to be a tactical buy more than a portfolio bet and we believe that these counters can give 20-25% upside in the...
- Wockhardt shares skyrocket 18% to fresh 52-week high. Here’s why?Shares of Wockhardt surged 18% in early trading to reach a new 52-week high of Rs 811.50 on NSE. The sharp increase followed the company's ...
- Wockhardt raises Rs 480 crore to pare debt, fund drug trialWockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of gl...
- Habil Khorakiwala on 3 things in the pipeline that can cause a re-rating for WockhardtHabil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to m...
- Wockhardt to reduce debt against share pledge to 26% from 65% now in FY24Khorakiwala-owned Humuza Consultants has pledged its entire 65.46% shares of Wockhardt with private lenders as of March 31, 2023, according...
- 3 Adani stocks among 15 BSE500 scrips that rallied 10-21% this weekThe biggest gainer among all was Brightcom Group, which gained 21 per cent to Rs 44.55.This is after the company reported a 163 per cent Yo...
- Wockhardt initiates phase-III clinical study of new antibiotic candidateWCK 5222 is a drug, which is entirely a new class of antibiotic known as "β-lactam ENHANCER", and is targeted for treatment of hospitalised...
- How Wockhardt Chairman Habil Khorakiwala plans to pull the company out of trouble45 years after he made a profound statement about dying only once, the chairman of Wockhardt would like to repeat it to investors, regulato...
- USFDA okays abridged clinical trial for antibiotic: WockhardtThe decision was based on the evaluation by USFDA of its preclinical and clinical data of phase I establishing safety and clinical scope of...
- Drug maker Wockhardt on fast track of innovationThe renewed optimism in the global outlook for anti-infective products vindicates the company’s long-term strategy.
- Wockhardt gets QIDP status for new antibiotic product from FDAQIDP status is granted to drugs identified by Centre for Disease Control, US, that act against pathogens which have a high degree of unmet ...
Load More
